Area of research
Pathology and Forensic Medicine · Oncology
Research interest
Research interests include Lymphoma Diagnosis and Treatment, CAR-T cell therapy research, Chronic Lymphocytic Leukemia Research, and CNS Lymphoma Diagnosis and Treatment.
Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy
Impact of extranodal involvement at CAR T-cell therapy on outcomes in patients with relapsed or refractory large B-cell lymphoma—Results from a multicenter cohort study
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma
Treatment and outcomes of progression of disease post–CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study
Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy
Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy
Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort study
Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma
Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study
A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma
Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma
Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions
High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study
A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma
Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 <scp>U.S.</scp> cancer centers
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma
Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy
OUTCOMES OF AUTOLOGOUS TRANSPLANT, ALLOGENEIC TRANSPLANT, AND CAR T CELL THERAPY IN TP53 ALTERED MANTLE CELL LYMPHOMA: A MULTI‐INSTITUTION RETROSPECTIVE ANALYSIS
Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma
Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL
Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma
ABCL-455 Multicenter Retrospective Analysis of Single-Route Prophylaxis in Aggressive B-Cell Lymphomas
Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers
Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions
Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant
Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis
Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study
Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy